[36] A study of 160 individuals with diabetes demonstrated that combination therapy (glucagon-like peptide-1 receptor agonist + sodium-glucose cotransporter-2 inhibitors) improved TAC, as measured by ABTS and DPPH, compared to these drugs alone or insulin [37]. Here, SLC5A2 is linked to diabetes mellitus.